These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9003208)

  • 1. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression.
    Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
    J Allergy Clin Immunol; 1997 Jan; 99(1 Pt 1):28-37. PubMed ID: 9003208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells.
    Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
    Am J Respir Cell Mol Biol; 1995 Dec; 13(6):692-702. PubMed ID: 7576707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
    Essayan DM; Huang SK; Undem BJ; Kagey-Sobotka A; Lichtenstein LM
    J Immunol; 1994 Oct; 153(8):3408-16. PubMed ID: 7930566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.
    Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
    J Pharmacol Exp Ther; 1997 Jul; 282(1):505-12. PubMed ID: 9223593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones.
    Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
    Biochem Pharmacol; 1997 Apr; 53(7):1055-60. PubMed ID: 9174120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2.
    Giembycz MA; Corrigan CJ; Seybold J; Newton R; Barnes PJ
    Br J Pharmacol; 1996 Aug; 118(8):1945-58. PubMed ID: 8864528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors.
    Verghese MW; McConnell RT; Strickland AB; Gooding RC; Stimpson SA; Yarnall DP; Taylor JD; Furdon PJ
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1313-20. PubMed ID: 7891349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
    Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor.
    Foissier L; Lonchampt M; Cogé F; Canet E
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1484-90. PubMed ID: 8819536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonists of cyclic nucleotide phosphodiesterase (PDE) isozymes PDE 3 and PDE 4 suppress lymphoblastic response to HLA class II alloantigens: a potential novel approach to preventing allograft rejection?
    Dousa MK; Moore SB; Ploeger NA; DeGoey SR; Dousa TP
    Clin Nephrol; 1997 Mar; 47(3):187-9. PubMed ID: 9105766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study.
    Gantner F; Tenor H; Gekeler V; Schudt C; Wendel A; Hatzelmann A
    J Allergy Clin Immunol; 1997 Oct; 100(4):527-35. PubMed ID: 9338548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
    Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
    Kelly JJ; Barnes PJ; Giembycz MA
    Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early increase in lymphocyte cyclic nucleotide phosphodiesterase activity upon mitogenic activation of human peripheral blood mononuclear cells.
    Meskini N; Hosni M; Nemoz G; Lagarde M; Prigent AF
    J Cell Physiol; 1992 Jan; 150(1):140-8. PubMed ID: 1309823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
    Greten TF; Sinha B; Haslberger C; Eigler A; Endres S
    Eur J Pharmacol; 1996 Mar; 299(1-3):229-33. PubMed ID: 8901027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function.
    Gantner F; Schudt C; Wendel A; Hatzelmann A
    Pulm Pharmacol Ther; 1999; 12(6):377-86. PubMed ID: 10587479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis.
    Banner KH; Roberts NM; Page CP
    Br J Pharmacol; 1995 Dec; 116(8):3169-74. PubMed ID: 8719792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.